Inclusion zone
Nothing crystallises the need for diversity and inclusion quite like pharma – a dose of unity makes us all feel, work and collaborate better – and now we must prescribe it throughout our industry
PharmaTimes -
December 2021
With Christmas just around the corner, it is only natural to reflect on the changes and trends of 2021 as we move closer to the new year. WInter is always challenging for the healthcare sector and this year it is particularly so, due to winter pressures coupled with the ongoing issues associated with COVID-19. However, there is still much to celebrate and reflect on as we head into 2022, and much to read in our latest issue.
EMIG’s Leslie Galloway takes a look at the key developments across the UK life sciences sector, offering an in-depth look at the notable barriers to access that remain as well as other changes including the NICE Methods and Process Review.
Maddy Farnworth examines how the pandemic has brought into sharp focus the importance of long-term sustainability and resilience of health systems. In her article, she considers three interconnected areas where the pharma industry needs to focus its attention to demonstrate its continued commitment to working for good.
OVID Health’s Jenny Ousbey also considers how sustainability has taken the spotlight in 2021 for the healthcare communications industry, with 2022 shaping up to be an important year for the sector to demonstrate its commitment to progress.
We also celebrate the winners of Clinical Researcher of the Year – The Americas 2021, with the exceptional talent of clinical researchers across the Americas having been recognised during a live virtual awards ceremony on 28 October.
The International Clinical Researcher of the Year 2022 competition is now open for entry!
December 2021 - magazine highlights
Why pharma needs to understand population health
Often misunderstood, the new focus on prevention and population health within the NHS can help pharma become a critical part of a more holistic, outcomes-led strategy for local systems, argues Oli Hudson
The UK life sciences sector: 2021 review
A look at the key developments across the sector this year
Maintaining the halo effect
What’s next for the pharmaceutical industry?
Pharmaceuticals in 2022
The pharma industry has been pivotal during the pandemic and this focus looks set to continue into 2022
Sustainability is the word
If there was a word to sum up healthcare communications in 2021 it would be ‘sustainability’…in all senses of the word
The ecosystem overtakes the producers in pharma and life sciences
M&A returns – but in a new form
The ever-increasing importance of the patient’s voice
We are currently witnessing a significant shift in healthcare – the rise of the empowered patient
Behavioural science: a new ally for Medical Affairs
Ben Routley and Mark Pringle take a look at how behavioural science techniques (BST) could be used to improve the impact of client communications
Patient file: Duchenne muscular dystrophy
PharmaTimes talks to Filippo Buccella, whose son Luca was diagnosed with the rare genetic disorder Duchenne muscular dystrophy (DMD) 28 years ago.He offers an in-depth look at Luca’s path to diagnosis, the treatment he has received as well as the advice he would offer to parents of a child with DMD.
